Ng Melissa, Cerezo-Wallis Daniela, Ng Lai Guan, Hidalgo Andres
Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A(∗)STAR), Singapore, Singapore.
Vascular Biology and Therapeutics Program and Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
Immunity. 2025 Jan 14;58(1):40-58. doi: 10.1016/j.immuni.2024.12.009.
There is a renewed interest in neutrophil biology, largely instigated by their prominence in cancer. From an immunologist's perspective, a conceptual breakthrough is the realization that prototypical inflammatory, cytotoxic leukocytes can be tamed to promote the survival and growth of other cells. This has sparked interest in defining the biological principles and molecular mechanisms driving the adaptation of neutrophils to cancer. Yet, many questions remain: is this adaptation mediated by reprogramming mature neutrophils inside the tumoral mass, or rather by rewiring granulopoiesis in the bone marrow? Why, in some instances, are neutrophils beneficial and in others detrimental to cancer? How many different functional programs can be induced in neutrophils by tumors, and is this dependent on the type of tumor? This review summarizes what we know about these questions and discusses therapeutic strategies based on our incipient knowledge of how neutrophils adapt to cancer.
人们对中性粒细胞生物学重新产生了兴趣,这在很大程度上是由它们在癌症中的突出作用所引发的。从免疫学家的角度来看,一个概念上的突破是认识到典型的炎症性、细胞毒性白细胞可以被驯化以促进其他细胞的存活和生长。这激发了人们对确定驱动中性粒细胞适应癌症的生物学原理和分子机制的兴趣。然而,许多问题仍然存在:这种适应是由肿瘤块内成熟中性粒细胞的重编程介导的,还是由骨髓中粒细胞生成的重新布线介导的?为什么在某些情况下中性粒细胞对癌症有益,而在其他情况下则有害?肿瘤能在中性粒细胞中诱导出多少种不同的功能程序,这是否取决于肿瘤的类型?这篇综述总结了我们对这些问题的了解,并基于我们对中性粒细胞如何适应癌症的初步认识讨论了治疗策略。